SCHEMBL4948924

SCHEMBL4948924

O=C(NCO)C(Cl)(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6592214 0.80
SCHEMBL11685139 0.78 EGLN1 (0.39)
SCHEMBL4280908 0.78 LMNA (0.43)
SCHEMBL7769403 0.76 LMNA (0.34)
SCHEMBL28639418 0.76 L3MBTL1 (0.40)
SCHEMBL7769400 0.76 LMNA (0.34)
SCHEMBL2797759 0.76 MMP1 (0.43)
SCHEMBL3620058 0.76
SCHEMBL988057 0.74 LMNA (0.36)
SCHEMBL7630141 0.74 L3MBTL1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3307718-A1 POLYMORPHS OF A PGES-1 INHIBITING TRIAZOLONE COMPOUND Glenmark Pharmaceuticals S.A. (CH) 2018-04-18 EP claimed
CN-107820489-A PGES 1 suppresses the polymorph of triazolone compound 格兰马克药品股份有限公司 2018-03-20 CN claimed
WO-2016199104-A1 POLYMORPHS OF A PGES-1 INHIBITING TRIAZOLONE COMPOUND GLENMARK PHARMACEUTICALS S.A. (CH) 2016-12-15 WO claimed
EP-3307718-B1 POLYMORPHS OF A PGES-1 INHIBITING TRIAZOLONE COMPOUND GLENMARK PHARMACEUTICALS SA (CH) 2020-12-30 EP disclosed
US-10457649-B2 Polymorphs of a mPGES-1 inhibiting triazolone compound GLENMARK PHARMACEUTICALS S.A. (CH) 2019-10-29 US disclosed
US-20180370923-A1 POLYMORPHS OF A mPGES-1 INHIBITING TRIAZOLONE COMPOUND Ichnos Sciences SA (CH) 2018-12-27 US disclosed
US-10112914-B2 Polymorphs of a mPGES-1 inhibiting triazolone compound GLENMARK PHARMACEUTICALS S.A. (CH) 2018-10-30 US disclosed
US-20180134671-A1 POLYMORPHS OF A PGES-1 INHIBITING TRIAZOLONE COMPOUND Ichnos Sciences SA (CH) 2018-05-17 US disclosed
EP-3307718-A1 POLYMORPHS OF A PGES-1 INHIBITING TRIAZOLONE COMPOUND Glenmark Pharmaceuticals S.A. (CH) 2018-04-18 EP disclosed
WO-2016199104-A1 POLYMORPHS OF A PGES-1 INHIBITING TRIAZOLONE COMPOUND GLENMARK PHARMACEUTICALS S.A. (CH) 2016-12-15 WO disclosed
US-8609610-B2 Inhibitors of the trypsin-like site of the proteasome and methods of use thereof TRUSTEES OF DARTMOUTH COLLEGE (US) 2013-12-17 US disclosed
US-20040092562-A1 Methods for treating inflammatory conditions or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC. 2004-05-13 US disclosed
EP-1363891-A2 ANTHRONE DERIVATIVES AND THEIR USE AS JNK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2003-11-26 EP disclosed
US-20030073732-A1 Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, INC. 2003-04-17 US disclosed
WO-2002066450-A2 ANTHRONE DERIVATIVES AND THEIR USE AS INK INHIBITORS SIGNAL PHARMACEUTICALS, INC. (US) 2002-08-29 WO disclosed
EP-0054715-A2 Esters of propanoic acid, preparation of these compounds, weed killers containing these compounds as active ingredients, use of such compounds and compositions for the control of weeds F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-06-30 EP disclosed
US-4143034-A LIGHTFAST STERLING DRUG INC. (US) 1979-03-06 US disclosed
US-4044153-A ANTIEDEMIC MERCK & CO., INC. (US) 1977-08-23 US disclosed
US-4029816-A ANTIHYPERTENSIVE, DIURETIC, SALURETIC MERCK & CO., INC. (US) 1977-06-14 US disclosed
US-3979361-A ANTIEDEMA, ANTIINFLAMMATORY MERCK & CO., INC. (US) 1976-09-07 US disclosed